Skip to content
    BTSG
    Earnings call· Dec 2025(Q4 FY25)

    BrightSpring Health Services Q4 FY25 earnings call BTSG

    Feb 27, 2026 Source

    Executive summary

    BrightSpring Q4 FY25 — Strong Growth, Strategic Divestiture & Acquisitions, and Exceeded Leverage Targets

    BrightSpring delivered robust Q4 and full-year FY25 results, driven by strong growth in Pharmacy Solutions and Provider Services, strategic M&A, and operational efficiencies. The company successfully divested its Community Living business and acquired significant home health assets, strengthening its balance sheet and exceeding leverage targets. Management is focused on continued volume growth, margin expansion through efficiency, and integrating new acquisitions, while navigating revenue headwinds from IRA and generic conversions in FY26.

    Highlights

    5

    • Total company revenue grew 29% in Q4 FY25 to $3.6 billion, and 28% for full year FY25 to $12.9 billion.

    • Adjusted EBITDA grew 41% in Q4 FY25 to $184 million, and 34% for full year FY25 to $618 million.

    • Leverage ratio decreased to 2.99x as of December 31, 2025, exceeding the target range of 3.0-3.5x.

    • Acquired 107 Amedisys and LHC home health branches for $239 million, adding $345 million in pro forma FY25 revenue.

    • Pharmacy Solutions adjusted EBITDA grew 44% in Q4 FY25, with specialty and infusion script growth of 30% YoY.

    Concerns

    3

    • Home and community pharmacy revenue declined 1% YoY in Q4 FY25 due to the unwinding of a large customer bankruptcy and exit of uneconomic customers.

    • Revenue headwinds of approximately $600 million expected in FY26 from IRA impact ($200M in specialty/infusion, $175M in home/community) and brand-to-generic conversions (over $400M in specialty/infusion).

    • Home and community script growth will be challenged until Q3 FY26 due to prior customer offboarding.

    Guidance & targets

    7
    CategoryTargetConfidence
    Total Revenue
    $14.45 billion to $15.0 billion
    high materiality
    High
    Pharmacy Solutions Revenue
    $12.6 billion to $13.1 billion
    medium materiality
    High
    Provider Services Revenue
    $1.85 billion to $1.9 billion
    medium materiality
    High
    Total Adjusted EBITDA
    $760 million to $790 million
    high materiality
    High
    EBITDA Contribution from Amedisys and LHC Acquisitions
    $30 million
    medium materiality
    High
    Leverage Ratio
    2.5x or below
    high materiality
    Medium
    Limited Distribution Drug (LDD) Launches
    16 to 20 plus
    medium materiality
    High

    Segment performance

    7
    SegmentRevenueYoYQoQMargin
    Pharmacy Solutions
    Adjusted EBITDA margin expanded by approximately 40 basis points versus last year. Total pharmacy script volume was 10.8 million in the quarter, driven by total pharmacy census growth. Total pharmacy volumes declined 1% due to a slight decline in home and community pharmacy volumes from customer bankruptcy and exit of uneconomic customers.
    Adjusted EBITDA growth: 44% YoYGross profit: $255 millionGross profit growth: 25% YoY
    		$3.2 billion32%—5.1% adjusted EBITDA margin
    Pharmacy Solutions - Infusion and Specialty
    Performance exceeded expectations, driven by market adoption of existing LDDs, new LDD wins, fee-for-service growth, and strong commercial execution. Infusion business performed in line with expectations with solid script volume growth.
    Script growth: 30% YoYLDD portfolio: 149New LDD launches in Q4: 5Total LDD launches in FY25: 24
    		$2.6 billion43%——
    Pharmacy Solutions - Home and Community Pharmacy
    Revenue declined due to divestitures associated with a customer that declared bankruptcy and decisions to exit specific uneconomic customers. Executed consistently across several end markets including behavioral, assisted living, hospice, and skilled nursing.
    		$593 million-1%——
    Provider Services
    Adjusted EBITDA margin expanded by approximately 50 basis points versus last year, primarily driven by economies of scale and efficiency.
    Adjusted EBITDA growth: 16% YoYGross profit: $158 millionGross profit growth: 17% YoY
    		$394 million13%—16.4% adjusted EBITDA margin
    Provider Services - Home Health Care
    Represents approximately 55% of Provider segment revenue. Growth driven by strong quality metrics, de novos, partnerships, preferred MA contracts, and strategic tuck-in acquisitions. Over 91% of branches at 4 stars or greater with 99.4% timely initiation of care.
    Average daily census: almost 35,000Average daily census growth: 15%
    		$217 million19%——
    Provider Services - Rehab Care
    Represents approximately 20% of Provider segment revenue. Growth driven by neuro rehab de novo additions, high patient satisfaction scores, and expansion of rehab and motion program into ALF and home settings.
    Persons served growth: 13%Hours billed growth in neuro rehab services: 17%
    		$75 million8%——
    Provider Services - Personal Care
    Represents approximately 25% of Provider segment revenue. Steady operational performance providing high-quality supportive care to seniors.
    Persons served: 16,175Persons served growth: 2%
    		$102 million4%——

    Operational metrics

    36
    Revenue CAGR
    22%
    7-year

    7-year Compound Annual Growth Rate for revenue.

    Adjusted EBITDA CAGR
    18%
    7-year

    7-year Compound Annual Growth Rate for adjusted EBITDA.

    Total Company Revenue
    $3.6 billion29% growth YoY
    Q4 FY25

    Revenue for continuing operations.

    Total Company Gross Profit
    $413 million22% growth YoY
    Q4 FY25

    Gross profit for continuing operations.

    Total Company Adjusted EBITDA
    $184 million41% increase YoY
    Q4 FY25

    Adjusted EBITDA for continuing operations.

    Adjusted EPS
    $0.33
    Q4 FY25

    Adjusted EPS for continuing operations.

    Adjusted EPS
    $1
    FY25

    Adjusted EPS for continuing operations for the full year.

    Adjusted EBITDA Margin
    4.8%20 bps increase vs 2024
    FY25

    Primarily driven by cost efficiencies from procurement and operational initiatives, along with generic revenue mix shift in Pharmacy.

    Leverage Ratio
    2.99xDeclined from 4.16x as of Dec 31, 2024
    As of Dec 31, 2025

    Exceeded target of 3.0-3.5x pro forma for Community Living transaction.

    Leverage Ratio (Pro Forma)
    2.6x
    Year-end 2025

    Pro forma for the Community Living transaction.

    Net Debt Outstanding
    $2.5 billion
    As of Dec 31, 2025
    Home Health Branches at 4 Stars or Greater
    over 91%
    Q4 FY25

    Reflects strong quality metrics.

    Home Health Timely Initiation of Care
    99.4%
    Q4 FY25

    Industry-leading level.

    Hospice CAHPS Overall Rating
    87%
    Q4 FY25

    Metrics remain well above the national average, with a top 5% ranked hospice program in the U.S.

    Rehab Outpatient Satisfaction
    100%
    Q4 FY25

    Patient satisfaction scores remain very strong.

    Rehab Home and Community Satisfaction
    98.4%
    Q4 FY25

    Patient satisfaction scores remain very strong.

    Personal Care Client Satisfaction
    4.6 out of 5vs 4.5 in Q3
    Q4 FY25

    Along with strong internal client records and quality indicators audit scores.

    Home and Community Pharmacy Dispensing Accuracy
    99.99%
    Q4 FY25
    Home and Community Pharmacy Order Completeness
    99.3%
    Q4 FY25
    Home and Community Pharmacy On-Time Delivery
    96.8%
    Q4 FY25
    Infusion Patient Satisfaction
    94%
    Q4 FY25

    One of only 2 providers in the country to receive the ACHC Ig distinction award.

    Specialty Pharmacy Medication Possession Ratio
    92.4%
    Q4 FY25

    Consistently strong, much stronger than the national average.

    Specialty Pharmacy Time to First Fill
    4.1 days
    Q4 FY25

    Much stronger than the national average.

    Onco360 MMIT Physician and Office Staff Satisfaction Survey Rank
    First
    H2 FY25

    Ranked first in the MMIT physician and office staff satisfaction survey.

    CareMed MMIT Physician and Office Staff Satisfaction Survey Rank
    Second
    H2 FY25

    Ranked second in the MMIT physician and office staff satisfaction survey.

    Pharmacy Solutions Adjusted EBITDA Margin
    4.7%improved YoY
    FY25

    Mentioned by analyst, confirmed by management as improving.

    Revenue Headwind from IRA
    $200 million
    FY26

    Expected revenue headwind in specialty and infusion from IRA.

    Revenue Headwind from Brand to Generic Conversions
    over $400 million
    FY26

    Expected revenue headwind in specialty and infusion from brand to generic conversions.

    Revenue Headwind from IRA
    $175 million
    FY26

    Expected revenue headwind in home and community pharmacy from IRA.

    Total Pharmacy Revenue Headwinds
    approximately $600 million
    FY26

    Combined headwinds from IRA and brand-to-generic conversions.

    Patients Referred to Home Health Not Receiving Service
    35%
    Current

    Estimated percentage of patients referred to home health who do not end up receiving the service.

    Home Health Impact - ER Visit Reduction
    15%
    Current

    Home health shown to reduce ER visits.

    Home Health Impact - Hospitalization Reduction
    25%
    Current

    Home health shown to reduce hospitalizations.

    Home Health Impact - Mortality Rate Reduction
    30%
    Current

    Home health shown to reduce mortality rates.

    Infusion AIS Presence
    about 30
    Current

    Plans to significantly expand AIS presence.

    Home and Community Pharmacy New Sales Representatives
    30
    FY26

    Adding reps to grow and penetrate attractive end markets.

    Industry KPIs

    3
    MetricValueDetails
    Pharmacy scripts specialty10.8 millionscripts
    Segment revenue operating income$11.4 billionUSD
    Adjusted EPS EBITDA leverage guidance$760 million to $790 millionUSD

    Deals & partnerships

    2
    nullDivestiture of Community Living business to streamline operations and focus on core patient populations.$835 million gross cash consideration

    The transaction was approved by the FTC. Expected to result in net after-tax cash proceeds of approximately $715 million, which will be primarily utilized for debt paydown to further improve leverage and strengthen the balance sheet.

    Amedisys and LHCAcquisition of home health assets to complement existing home health business and expand geographic presence.$239 million purchase price

    Acquired 107 branches in a two-part transaction on December 1 and December 31, 2025. Fully funded from cash on hand. Assets are complementary geographically and in the same markets as existing hospice locations.

    Risks & headwinds

    5
    Decline in home and community pharmacy revenueQ4 FY25, script challenges until Q3 FY26

    1% YoY decline in Q4 FY25

    Mitigation: Unwinding of a large customer going through bankruptcy and decision to exit specific uneconomic customers. Forward year guidance contemplates various scenarios for the ongoing bankruptcy process. Enhancing go-to-market strategy, investing in growth resources, and driving expansion in end markets.

    Revenue headwind from IRAFY26

    approximately $200 million

    Mitigation: Working productively with payers regarding enhanced dispensing fees to mitigate impact. Government relations team active.

    Revenue headwind from brand-to-generic conversionsFY26

    over $400 million

    Mitigation: While revenue declines, margins often improve. Company drives generic utilization and benefits from procurement. Focus on LDD wins and fee-for-service business.

    Revenue headwind from IRAFY26

    approximately $175 million

    Mitigation: Working productively with payers regarding enhanced dispensing fees. Leveraging scale, platform, and operational improvements.

    Uncertainty regarding future home health ratesFuture

    Baseline view is flat rates

    Mitigation: Optimistic due to constructive conversations and value of home health. See an 'unbelievable runway' over the next 5-10 years. Base case is flat, but potential for positive rate increases.

    What to watch in Q1 FY26

    5

    Community Living Divestiture

    End of Q1 FY26
    CurrentApproved by FTC, expected to close
    TargetClosed

    Why it matters

    The closing of this divestiture will provide $715 million in net cash proceeds for debt paydown, significantly impacting the company's leverage and capital allocation flexibility.

    Earlier this year, the Community Living divestiture transaction was approved by the FTC, and at this time, we expect the transaction to close at the end of the first quarter.

    Q&A highlights

    7

    What are the greatest swing factors that could create upside or challenges for the FY26 guidance?

    Management expects consistency, focusing on continued volume growth through sales investments (home health, hospice, infusion, home & community in select markets), realizing benefits from Lean Sigma, tech, and AI projects, and successful integration of Amedisys/LHC acquisitions.

    “I mean as we look out for the year and try to ensure execution, continuing to drive volume growth in each of the businesses is going to be important.”

    asked by Albert Rice · answered by Jon Rousseau

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Portfolio Optimization

    BrightSpring is streamlining its operations through strategic portfolio adjustments. The divestiture of the Community Living business, approved by the FTC, is expected to close by the end of Q1 FY26, yielding approximately $715 million in net after-tax cash proceeds primarily for debt paydown. Concurrently, the company acquired 107 Amedisys and LHC home health branches for $239 million, fully funded by cash on hand, which generated $345 million in pro forma FY25 revenue and are expected to contribute $30 million to FY26 adjusted EBITDA.

    02

    Strong Financial Performance and Balance Sheet

    The company reported robust financial results, with full year FY25 revenue of $12.9 billion (up 28% YoY) and adjusted EBITDA of $618 million (up 34% YoY). Adjusted EBITDA margin expanded by 20 basis points to 4.8%, driven by procurement and operational initiatives. Operating cash flow reached $490 million in FY25. The leverage ratio significantly improved to 2.99x as of December 31, 2025, down from 4.16x in FY24, surpassing the target of 3.0-3.5x.

    03

    Pharmacy Solutions Growth Drivers

    Pharmacy Solutions revenue grew 32% in Q4 FY25, with adjusted EBITDA up 44%. Specialty and infusion script growth was 30% YoY, driven by market adoption of existing LDDs, new LDD wins, and fee-for-service growth. The LDD portfolio now stands at 149, with 24 launches in FY25. The company expects 16-20+ LDD launches over the next 12-18 months, including rare, orphan, and infusion LDDs, expanding beyond oncology.

    04

    Provider Services Segment Performance

    Provider Services revenue grew 13% in Q4 FY25, with adjusted EBITDA up 16% and a margin of 16.4%, expanding 50 basis points YoY. Home health care, representing 55% of segment revenue, grew 19% with average daily census up 15% to nearly 35,000. Rehab care revenue grew 8% with persons served up 13%, and personal care revenue grew 4% with persons served up 2%.

    05

    Operational Excellence and Quality Outcomes

    BrightSpring emphasizes its commitment to high-quality, patient-centric care, reflected in strong patient satisfaction scores across all segments. Home health branches maintain over 91% at 4 stars or greater, and hospice metrics are well above national averages. The company continues to invest in technology, AI, and Lean Sigma projects to drive efficiency and enhance operational processes, contributing to margin expansion.

    06

    Community Engagement and Foundation Launch

    The company highlighted its commitment to employees and communities through various support programs, including college scholarships and nursing school partnerships. BrightSpring has launched an enterprise foundation, the BrightSpring Health Foundation, to formally carry on its community and patient support activities, aiming to positively impact lives for decades to come.

    AI-generated summary of the company’s earnings call. Not investment advice.